Quantcast

Latest Calcitonin gene-related peptide Stories

2014-04-30 12:30:06

Targeting CGRP, Intranasal Capsaicin Shows Potential in Offering Rapid Pain Relief to Numerous Sufferers in Need of Additional Treatment Options NEW YORK, April 30, 2014 /PRNewswire/ -- Real-world patient case series analysis supporting the use of intranasal capsaicin as an effective rapid treatment for severe headache and migraine pain will be presented at the 66(th) American Academy of Neurology (AAN) Annual Meeting in Philadelphia, PA on Thursday, May 1, 2014 during Poster Session...

2014-04-08 08:29:08

CARDIFF, Calif., April 8, 2014 /PRNewswire/ -- NI Research has released the April issue of NeuroPerspective, which reviews and assesses migraine therapeutics in development. Migraine is the most common of all neurological disorders. Based on epidemiological studies done in the US and Europe during the 1990s, approximately 12.6% of the population experiences migraine in a given year, with 18% suffering from migraine at some point in their lifetimes. It is estimated that there are 36...

2014-01-16 08:27:11

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, January 16, 2014 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Gilead Sciences Inc. (NASDAQ: GILD), Eli Lilly & Co. (NYSE: LLY), Allergan Inc. (NYSE: AGN), Incyte Corporation (NASDAQ: INCY), and Varian Medical Systems Inc. (NYSE: VAR). Today's readers may access these reports free of charge - including full price targets, industry analysis and...

2014-01-13 08:26:30

Deal Represents Positive Milestone for Alternative R&D Funding Strategy INDIANAPOLIS, Jan. 13, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced that, based on positive Phase 2 data, it has acquired all development rights for a calcitonin gene-related peptide (CGRP) antibody currently being studied as a potential treatment for the prevention of frequent, recurrent migraine headaches. CGRP is a sensory neuropeptide with vascular and pro-inflammatory effects, two...

2014-01-08 08:28:02

SAN MATEO, Calif., Jan. 8, 2014 /PRNewswire/ -- Labrys Biologics Inc., a biotechnology company focused on treatments for migraine, today announced that patients are now being enrolled in two separate Phase 2b clinical studies of LBR-101 (formerly RN-307) as a subcutaneous once-monthly treatment for the prevention of frequent migraines. The first study is enrolling subjects with chronic migraine, who experience at least 15 headache days per month. The second study is enrolling subjects...

2013-10-15 21:04:49

Scientists at the University of Washington have used genetic engineering to identify a population of neurons that tell the brain to shut off appetite. Their study, "Genetic identification of a neural circuit that suppresses appetite," was published Oct. 13 in Nature. To identify these neurons, or cells that process and transmit information in the brain, researchers first considered what makes an animal lose its appetite. There are a number of natural reasons, including infection, nausea,...


Word of the Day
barratry
  • The offense of persistently instigating lawsuits, typically groundless ones.
  • An unlawful breach of duty on the part of a ship's master or crew resulting in injury to the ship's owner.
  • Sale or purchase of positions in church or state.
This word ultimately comes from the Old French word 'barater,' to cheat.
Related